Logic Will Prevail in the EU Financial Transaction Tax Debate

January 17th, 2012

As Will McBride posted this morning, imposing a financial transactions tax seems to be all the rage in the European Union.  France says it will go it alone if need be.  Germany claims it’s dedicated to joining.  And now we’re seeing indicators that Austria and Italy could jump on the bandwagon.

The reality is that it will never happen for an extended period of time.  I cannot express the word never enough.

Think about it this way:

You own a small business that sells the same good as all 30 businesses in your neighborhood.  Add to this the fact that each business is directly adjacent to or across from another so that the effort customers must exert to search for the best price is minimal.  For some reason, you increase the price of your good by $1.  On a price basis, you will lose all of your customers to your competitors.

This is how France is thinking of doing business.  Except they claim that if everyone gets on the bandwagon, no one will lose business (all prices would increase by $1).  Sounds reasonable but for one fatal flaw: everyone has an incentive to discount their price if everyone else is selling at that $1 premium.  One by one, the businesses would drop price to its pre-premium level.

This is why a worldwide move to institute FTTs has never occurred.  The financial incentives to break from the agreement are simply too high.  Knowing this, rational countries such as the United Kingdom look forward and reason backward.  Not only will the experiment cost money, it will fail.

Keep an eye out for more countries to join the FTT chorus, but unless it includes every industrialized financial capital in the world, the status quo will remain—as well it should.

Tags: Financial Transaction, Tax

Even the Naysayers Say Now Is the Time to Buy

January 9th, 2012

Business School professors Eli Beracha of East Carolina University and Ken H. Johnson of Florida International University have done extensive research on which makes more sense financially: to rent or own a home. They published, Lessons from Over 30 Years of Buy versus Rent Decisions: Is the American Dream Always Wise? In their paper, the professors do not dispute the social benefits of homeownership:

“Home ownership is touted as the “American Dream”. It is credited with enhancing wealth, increasing civic pride, improving self-esteem, crime prevention, child development, and better educational outcomes, among other benefits. This paper does not dispute any of these claims.”

What the professors were proposing is that homeownership is not a better investment strategy than renting. The firs

Read more…

How to Resolve mistakes in your CIBIL credit report ?

January 8th, 2012

Did you come across many errors and mistakes while checking your CIBIL report status? Are you wondering how to clear yourself out of CIBIL defaulter list? In this article you will see what can be done to correct your CIBIL report. Firstly let’s understand the type of errors that can be on your CIBIL report. Before that, the first thing you need to do , apply for your CIBIL Credit Report Online

1. Error in your CIBIL Credit Report Account Details

Banks keep on updating CIBIL about your credit behaviour on monthly basis. So, at the time of entering some data, it might happen that some human error happens. Even though these are human mistakes, still they are responsible and correctly blamed for a lot of complaints. L

Read more…

Tags: Report

Telormedix raises 7.5 Million CHF in financing round

January 6th, 2012

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has raised 7.5 Million CHF from existing investors Aravis Venture (Basel, Switzerland) and Proquest Investments (Princeton-San Diego, USA).

The money raised in this financing round will be used to further advance Telormedix’s promising product candidates through preclinical and clinical trials. TMX-101, the Company’s lead product, is in a Phase I/II clinical trial for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). In addition, the Company achieved significant preclinical results in October 2011 for TMX-202, a compound developed for the safe and effective topical treatment of skin cancer.

Read more…

Tags: Chf, Million Chf